Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.32
BMRN's Cash to Debt is ranked higher than
58% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. BMRN: 1.32 )
BMRN' s 10-Year Cash to Debt Range
Min: 0.12   Max: No Debt
Current: 1.32

Equity to Asset 0.66
BMRN's Equity to Asset is ranked higher than
72% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. BMRN: 0.66 )
BMRN' s 10-Year Equity to Asset Range
Min: -0.66   Max: 0.97
Current: 0.66

-0.66
0.97
F-Score: 2
Z-Score: 9.98
M-Score: -1.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.48
BMRN's Operating margin (%) is ranked higher than
80% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. BMRN: -16.48 )
BMRN' s 10-Year Operating margin (%) Range
Min: -1075   Max: 13.41
Current: -16.48

-1075
13.41
Net-margin (%) -20.35
BMRN's Net-margin (%) is ranked higher than
79% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. BMRN: -20.35 )
BMRN' s 10-Year Net-margin (%) Range
Min: -1025   Max: 54.7
Current: -20.35

-1025
54.7
ROE (%) -9.74
BMRN's ROE (%) is ranked higher than
80% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. BMRN: -9.74 )
BMRN' s 10-Year ROE (%) Range
Min: -751.65   Max: 39.6
Current: -9.74

-751.65
39.6
ROA (%) -6.15
BMRN's ROA (%) is ranked higher than
82% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. BMRN: -6.15 )
BMRN' s 10-Year ROA (%) Range
Min: -76.62   Max: 18.88
Current: -6.15

-76.62
18.88
ROC (Joel Greenblatt) (%) -18.38
BMRN's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. BMRN: -18.38 )
BMRN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -433   Max: 24.82
Current: -18.38

-433
24.82
Revenue Growth (3Y)(%) 9.20
BMRN's Revenue Growth (3Y)(%) is ranked higher than
81% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BMRN: 9.20 )
BMRN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 97.7
Current: 9.2

0
97.7
EPS Growth (3Y)(%) 24.20
BMRN's EPS Growth (3Y)(%) is ranked higher than
90% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. BMRN: 24.20 )
BMRN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 36.5
Current: 24.2

0
36.5
» BMRN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BMRN Guru Trades in Q2 2014

Manning & Napier Advisors, Inc 244,060 sh (+42.30%)
Frank Sands 11,925,248 sh (+22.47%)
John Griffin 2,100,000 sh (+1.94%)
Steven Cohen 90,100 sh (unchged)
John Burbank Sold Out
Ray Dalio Sold Out
PRIMECAP Management 8,064,219 sh (-1.22%)
Columbia Wanger 1,167,800 sh (-15.93%)
» More
Q3 2014

BMRN Guru Trades in Q3 2014

Joel Greenblatt 3,885 sh (New)
Paul Tudor Jones 5,913 sh (New)
Steven Cohen 675,600 sh (+649.83%)
Manning & Napier Advisors, Inc 288,180 sh (+18.08%)
John Griffin 2,230,000 sh (+6.19%)
Frank Sands 12,098,628 sh (+1.45%)
PRIMECAP Management 8,043,918 sh (-0.25%)
Columbia Wanger 853,800 sh (-26.89%)
» More
Q4 2014

BMRN Guru Trades in Q4 2014

Louis Moore Bacon 56,100 sh (New)
RS Investment Management 94,400 sh (New)
Frank Sands 12,183,113 sh (+0.70%)
Frank Sands 12,183,113 sh (+0.70%)
John Griffin 2,230,000 sh (unchged)
Manning & Napier Advisors, Inc 288,180 sh (unchged)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 8,016,518 sh (-0.34%)
Columbia Wanger 416,200 sh (-51.25%)
Steven Cohen 74,600 sh (-88.96%)
» More
Q1 2015

BMRN Guru Trades in Q1 2015

Joel Greenblatt 4,195 sh (New)
Frank Sands 12,335,452 sh (+1.25%)
PRIMECAP Management 8,025,008 sh (+0.11%)
John Griffin 2,230,000 sh (unchged)
Columbia Wanger Sold Out
Steven Cohen Sold Out
Manning & Napier Advisors, Inc Sold Out
Louis Moore Bacon 27,500 sh (-50.98%)
RS Investment Management 33,900 sh (-64.09%)
» More
» Details

Insider Trades

Latest Guru Trades with BMRN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.20
BMRN's P/B is ranked higher than
56% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. BMRN: 8.20 )
BMRN' s 10-Year P/B Range
Min: 3.68   Max: 28.5
Current: 8.2

3.68
28.5
P/S 23.80
BMRN's P/S is ranked higher than
60% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. BMRN: 23.80 )
BMRN' s 10-Year P/S Range
Min: 3.37   Max: 94.86
Current: 23.8

3.37
94.86
EV-to-EBIT -150.30
BMRN's EV-to-EBIT is ranked higher than
66% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: -150.30 )
BMRN' s 10-Year EV-to-EBIT Range
Min: -1611.4   Max: 67133.8
Current: -150.3

-1611.4
67133.8
Current Ratio 4.98
BMRN's Current Ratio is ranked higher than
75% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. BMRN: 4.98 )
BMRN' s 10-Year Current Ratio Range
Min: 0.9   Max: 18.94
Current: 4.98

0.9
18.94
Quick Ratio 4.25
BMRN's Quick Ratio is ranked higher than
73% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. BMRN: 4.25 )
BMRN' s 10-Year Quick Ratio Range
Min: 0.82   Max: 18.77
Current: 4.25

0.82
18.77
Days Inventory 520.82
BMRN's Days Inventory is ranked higher than
77% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 520.82 )
BMRN' s 10-Year Days Inventory Range
Min: 106.92   Max: 917.29
Current: 520.82

106.92
917.29
Days Sales Outstanding 79.91
BMRN's Days Sales Outstanding is ranked higher than
79% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. BMRN: 79.91 )
BMRN' s 10-Year Days Sales Outstanding Range
Min: 50.96   Max: 212.92
Current: 79.91

50.96
212.92

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 794.90
BMRN's Price/Net Current Asset Value is ranked higher than
52% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. BMRN: 794.90 )
BMRN' s 10-Year Price/Net Current Asset Value Range
Min: 2.98   Max: 208.24
Current: 794.9

2.98
208.24
Price/Tangible Book 15.70
BMRN's Price/Tangible Book is ranked lower than
51% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. BMRN: 15.70 )
BMRN' s 10-Year Price/Tangible Book Range
Min: 2.15   Max: 103.23
Current: 15.7

2.15
103.23
Price/DCF (Projected) 28.30
BMRN's Price/DCF (Projected) is ranked higher than
87% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. BMRN: 28.30 )
BMRN' s 10-Year Price/DCF (Projected) Range
Min: 19.71   Max: 234.29
Current: 28.3

19.71
234.29
Price/Median PS Value 1.60
BMRN's Price/Median PS Value is ranked higher than
75% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. BMRN: 1.60 )
BMRN' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 9.94
Current: 1.6

0.26
9.94
Earnings Yield (Greenblatt) -0.70
BMRN's Earnings Yield (Greenblatt) is ranked higher than
82% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. BMRN: -0.70 )
BMRN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.7   Max: 3.3
Current: -0.7

-0.7
3.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BM8.Germany,
Biomarin Pharmaceutical Inc was incorporated in Delaware on October 1996 and began operations on March 21, 1997. It develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company selects product candidates for diseases and conditions that represent an unmet medical need. Its product portfolio is comprised of five approved products and multiple investigational product candidates. Approved products include VIMIZIM (elosulfase alfa), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). The Company is conducting clinical trials on several investigational product candidates for the treatment of various diseases including PEG PAL, an enzyme substitution therapy for the treatment of PKU; BMN 701, an enzyme replacement therapy for Pompe disease, a glycogen storage disorder; BMN 673, an orally available poly-ADP ribose polymerase inhibitor for the treatment of patients with certain cancers BMN 111, a peptide therapeutic for the treatment of achondroplasia, the cause of dwarfism: and BMN 190 for the treatment of late infantile neuronal ceroid lipofuscinosis(CLN2), lysomal storage disorder affecting the brain. The Company faces competition from biological products approved through an abbreviated regulatory pathway. The Company operates in a regulated industry, which is subject to significant federal, state, local and foreign regulation.
» More Articles for BMRN

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
You Can No Longer Ignore Biotech Feb 07 2014 
Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

More From Other Websites
Cramer shuts down this market's haters May 22 2015
Biotech stock set to double May 21 2015
Sarepta’s Feast May Not Satisfy May 20 2015
Sarepta Gets FDA Green Light to Submit Application May 20 2015
These biotech names are ripe for mergers: Analysts May 10 2015
10-Q for BioMarin Pharmaceutical, Inc. May 07 2015
BioMarin Pharmaceutical (BMRN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the... May 07 2015
Why These 4 Biotech Stocks Could Be the Next Buyout Targets May 07 2015
Biotech takeover targets May 06 2015
Why BioMarin's New Drug Application is Good News for Sarepta Therapuetics May 06 2015
Rare disease stocks fly on Alexion acquisition May 06 2015
Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review May 06 2015
Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. May 05 2015
BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report May 05 2015
No, the Biotech Boom Isn't Over May 04 2015
BioMarin Q1 Loss Narrower than Expected, '15 View Revised - Analyst Blog May 01 2015
BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th;... May 01 2015
BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th;... May 01 2015
BioMarin Pharmaceutical (BMRN) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015
BioMarin reports 1Q loss Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK